Effect of Brimonidine on Corneal Thickness
Information source: Augenarztpraxis Breisach
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Impact of Brimonidine on the Cornea
Intervention: brimonidine 0.1% (Drug); placebo (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Augenarztpraxis Breisach Official(s) and/or principal investigator(s):
Matthias Grueb, Priv. Doz. Dr., Study Director, Affiliation: Augenarztpraxis Breisach
Overall contact:
Matthias Grueb, Priv. Doz. Dr., Phone: 004976677766, Email: matthias.grueb@web.de
Summary
Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication which is
widely used in glaucoma treatment. Although it is known that it is quickly taken up by the
cornea following topical administration and that the cornea has alpha-2 adrenoceptors there
are only few studies available on the impact brimonidine has on the cornea. The aim of the
study is to find out
1. whether topical administration of brimonidine results in interaction with corneal
alpha-2 adrenoceptors in terms of an increase in corneal thickness and
2. whether there are any differences between the response corneal epithelium, stroma and
endothelium show to alpha-2 adrenoceptor stimulation.
Clinical Details
Official title: Effect of Brimonidine on Corneal Thickness
Study design: Observational Model: Case Control, Time Perspective: Prospective
Primary outcome: corneal thickness
Secondary outcome: intraocular pressure
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- healthy, 18-99 years, normal ophthalmologic history, consent to participate in the
study
Exclusion Criteria:
- any serious medical or neurologic conditions and/or regular use of local or systemic
medications
Locations and Contacts
Matthias Grueb, Priv. Doz. Dr., Phone: 004976677766, Email: matthias.grueb@web.de
Augenarztpraxis, Breisach, Baden-Wuerttemberg 79206, Germany; Recruiting
Matthias Grueb, Priv. Doz. Dr., Phone: 004976677766, Email: matthias.grueb@web.de
Matthias Grueb, Priv. Doz. Dr., Principal Investigator
Additional Information
Starting date: December 2010
Last updated: December 2, 2010
|
